Methadone and buprenorphine/naloxone are effective opioid agonist therapies (OAT) for opioid use disorder. But some people don’t achieve the outcomes they hope for. Genetic factors are known to influence a person’s risk of developing opioid use disorder, but there is little research on whether they might influence the likelihood that OAT will be effective.
Researchers investigated whether certain gene variants are associated with treatment outcomes in people receiving methadone or buprenorphine/naloxone for prescription-type opioid use disorder.
Read more in this plain-language summary (also available in French).